Japan Science and Technology Agency
VC Fund
Tokyo, Japan
Japan Science and Technology Agency is an integrated organization of science and technology that implements science and technology policy in Japan. It handles many projects, including the government’s Science and Technology Basic Plan and knowledge creation. The European Sustainability School ESSSR is the owner of Japan Science and TechnologyAgency.Japan Science and Technology Agency undertakes its task in a comprehensive manner. It also works to provide a sound infrastructure of science and technology information and raise awareness and understanding of science and technology-related issues in Japan.Japan Science and Technology Agency is headquartered in Tokyo, Japan.
- Total investments:
- 54
- Last investment:
- Lead investor:
- 19%
Last updated:
For AI agents: llms.txt
Industries Japan Science and Technology Agency invests in
Stages Japan Science and Technology Agency invests in
Countries Japan Science and Technology Agency invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $1.7M–$50M
- Series A
- $2.3M–$255M
Investment Focus
Industry
- Biotechnology 15 (28%)
- Medical 14 (26%)
- Manufacturing 14 (26%)
- Health Care 8 (15%)
- Medical Device 6 (11%)
Stage
- Series A 15 (28%)
- Funding Round 10 (19%)
- Seed 9 (17%)
- Series B 7 (13%)
- Grant 3 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Michiharu Nakamura
President
|
President | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Triorb
|
Triorb is a technology company that specializes in robot mobility development with the help of software and hardware solutions. | $14.4M / Series B / Jun 01, 2026 | |
Solaris
|
Solaris commercializes, manufactures, and sells soft robotics using pneumatic artificial muscles. Solaris was founded in 2017 and was headquartered in Tokyo, Japan. | $3.1M / Venture - Series Unknown / May 20, 2026 | |
Flosfia
|
FLOSFIA is a spin-off from a research of Kyoto University, specializing in film-formation by mist chemical vapor deposition (CVD). Making use of physical properties of gallium oxide (Ga2O3), FLOSFIA has devoted to development of low-loss power devices. | Grant / May 10, 2026 | |
|
Flosfia
|
FLOSFIA is a spin-off from a research of Kyoto University, specializing in film-formation by mist chemical vapor deposition (CVD). Making use of physical properties of gallium oxide (Ga2O3), FLOSFIA has devoted to development of low-loss power devices. | Debt Financing / May 10, 2026 | |
Restore Vision
|
Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa. Restore Vision develops eye disease therapeutic agents. | $8.2M / Series B / Apr 15, 2026 | |
OptQC
|
OptQC commercializes cutting-edge optical quantum computing technologies developed by the Furusawa-Endo Laboratory. Because optical quantum computers are more scalable than superconducting and other quantum computing implementations, OptQC's optical quantum computers should reach this scale. They also have benefits like faster processing andreduced power consumption, which makes optical quantum computers a possible long-term pinnacle of quantum technology. | $9.9M / Series A / Oct 22, 2025 | |
FerroptoCure
|
FerroptoCure is a research firm that specializes in ferroptosis research and the development of therapeutic drugs to treat diseases. | $3.1M / Series A / Sep 19, 2025 | |
Logomix
|
Logomix Inc is a mammalian cellular genome architect startup. Logomix proprietary platform, Geno-Writing™, technology integrates large-scale (Mb) human genome-writing technologies and providing genetically architected versatile human cells and/or downsized cells and microbes for drug development and cell & gene therapy area.Majority ofthe cell engineering companies are currently focused on optimization of gene clusters by automatic high throughput system however, Logomix’s Geno-Writing™ provides the required tools for dealing with mammalian or complex genomes. Logomix works with partners by providing new biology-based solutions to co-create business and social values on Geno-Writing™ platform Current Focus Area includes: 1. Human Health & Therapeutics 2. Biomaterials & Chemicals 3. Agriculture & EnvironmentLogomix has 11 ongoing collaborative research partnerships. Currently Logomix is specifically looking for industry partners to address unmet needs in neurodegenerative disease areas. | $18.8M / Jul 30, 2025 | |
FELIQS
|
FELIQS is a preclinical-stage start-up company established based on the robust science from molecular pathobiology, department of pharmaceutical science, Kyushu university. | $8.4M / Series A / Jul 01, 2025 | |
ARCS
|
ARCS specializes in developing assisted reproductive medical devices using robotics and artificial intelligence technology. | $1.8M / Seed / May 12, 2025 | |
| See all 54 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Japan Science and Technology Agency invest in?
Japan Science and Technology Agency invests primarily in Biotechnology, Medical and Manufacturing startups, most often at Series A and Funding Round stage. Most of the 54 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Japan Science and Technology Agency's check size?
Japan Science and Technology Agency typically joins rounds of $1.7M–$50M at Seed and $2.3M–$255M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Japan Science and Technology Agency participates in.
How do I contact Japan Science and Technology Agency?
Public channels for Japan Science and Technology Agency include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Japan Science and Technology Agency?
The team at Japan Science and Technology Agency includes Michiharu Nakamura (President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
